In 2012, Nereus was acquired by Triphase Research and Development. Previously Nereus had been focused on the commercialization of natural small-molecule compounds for the treatment of inflammatory diseases, cancer, and infectious diseases. The Company had access to novel chemical libraries as well as a proprietary marine cell culture technology. The firm is developing an integrated platform technologies used to identify novel biologically active compounds. Nereus Pharmaceuticals has created a pipeline of two pre-clinical candidates and an additional three new chemical entity (NCE) leads currently in development. Nereus intends to file an IND for both preclinical products in 2005. These targeted anticancer compounds are 1) a novel selective tumor vascular disrupting agent (VDA) for the treatment of certain solid tumors such as colon carcinoma, non small cell lung, thyroid and breast cancer and 2) a second generation proteasome inhibitor (the same class of therapeutic as Millennium's Velcade) for the treatment of multiple myeloma and/or solid tumors. Nereus also believes that its development pipeline should enable the Company to take an additional one to two compounds into human clinical trials in 2006/2007. All of Nereus' early compounds are in high value therapeutic classes such as targeted cancer treatments, which, if approved, would have substantial market potential. Over twenty-five additional development leads comprise the Company's current portfolio. I
